Guideline Recommendations for Management of Low‑Grade Squamous Intraepithelial Lesion (LSIL)

1. General Principles (All Populations)

• Immediate colposcopy is the preferred next step for most adult women (ages 21‑65) with LSIL, although repeat cytology or HPV DNA testing at 12 months are acceptable alternatives based on age and clinical context. 1
• Routine diagnostic excisional procedures (e.g., LEEP) should not be performed for initial LSIL management unless histologically confirmed CIN 2/3 is present, to avoid overtreatment. 1
• When HPV DNA testing is used for follow‑up, it must not be performed at intervals shorter than 12 months. 1

2. Age‑Stratified Management

2.1 Adolescents (≤ 20 years)

• Annual cytology surveillance is recommended instead of immediate colposcopy because LSIL in this group usually reflects a transient HPV infection with a high spontaneous regression rate (~51%). 2
• At the 12‑month follow‑up visit, refer to colposcopy only if HSIL or a higher grade lesion is detected on repeat cytology. 2
• At the 24‑month follow‑up visit, refer to colposcopy if ASC‑US or a higher grade lesion is present on repeat cytology. 2
• HPV DNA testing should not be performed or used to guide management in adolescents, even if the test is inadvertently obtained. 2

2.2 Adult Women (21‑65 years)

2.2.1 Immediate Colposcopy (Preferred Pathway)

• Direct referral to colposcopy allows immediate identification of CIN 2/3 lesions. 1
• Endocervical sampling is recommended when no visible lesions are identified during colposcopy. 1
• If colposcopy does not reveal CIN, repeat cytology should be performed at 12 months; routine screening can resume after two consecutive negative cytology results. 1

2.2.2 Repeat Cytology Strategy

• Perform cervical cytology at 6‑month and 12‑month intervals. 1
• Refer to colposcopy if ASC‑US or a higher grade abnormality is detected on any repeat cytology. 1
• Return to routine screening after obtaining two consecutive negative cytology results. 1

2.2.3 HPV DNA Testing at 12 Months

• Conduct HPV DNA testing at the 12‑month visit (testing earlier than 12 months is not recommended). 1
• Refer to colposcopy if the HPV test is positive. 1
• If the HPV test is negative, resume routine screening. 1

2.3 Postmenopausal Women

• Management options are identical to those for adult women: reflex HPV DNA testing, repeat cytology at 6‑ and 12‑month intervals, or immediate colposcopy. 2
• If HPV testing is negative or colposcopy shows no CIN, repeat cytology at 12 months. 2
• If HPV testing is positive or repeat cytology reveals ASC‑US or higher, proceed to colposcopy. 2

2.4 Pregnant Women (Non‑Adolescent)

• Colposcopy is the preferred initial approach for pregnant women with LSIL. 2
• Endocervical curettage is contraindicated during pregnancy. 2
• When the initial colposcopy shows no CIN 2/3 or cancer, schedule postpartum follow‑up rather than additional colposcopic examinations during pregnancy. 2

Management of Low‑Grade Squamous Intraepithelial Lesion (LSIL)

Adolescents (≤ 20 years)

• Annual cytology (Pap test) is recommended instead of immediate colposcopy for adolescents with LSIL. 3, 4, 5
• At the 12‑month follow‑up visit, referral to colposcopy is indicated only if a high‑grade lesion (HSIL or greater) is detected. 3, 4, 5
• At the 24‑month follow‑up visit, referral to colposcopy is indicated if any atypical squamous cells (ASC‑US or greater) are present. 3, 4, 5
• HPV DNA testing should not be used to guide management in this age group, even if performed inadvertently. 3, 4
• LSIL in adolescents commonly reflects a transient HPV infection, with regression observed in approximately 51 % of cases in one study. 5

Adult Women (21–50 years)

• Three evidence‑based management pathways are acceptable for adult women with LSIL:

Postmenopausal Women

• Management options mirror those for adult women and include: reflex HPV DNA testing, repeat cytology at 6 months and 12 months, or immediate colposcopy. 3, 4
• If HPV testing is negative or colposcopy does not reveal CIN, a repeat cytology is performed at 12 months. 3, 4
• If HPV testing is positive or repeat cytology shows ASC‑US or greater, colposcopy is recommended. 3, 4

Pregnant Women (non‑adolescent)

• Colposcopy is the preferred initial approach for pregnant women with LSIL. 3, 4, 6
• Deferring colposcopy until ≥ 6 weeks postpartum is acceptable because the risk of invasive cancer during pregnancy is low (≈ 5 per 100 000 pregnancies) and postpartum regression of CIN 1 occurs in about 36 % of cases. 3, 4, 5
• Endocervical curettage is not recommended in pregnancy. 3, 4, 6
• When the initial colposcopy shows no CIN 2, CIN 3, or cancer, follow‑up should be scheduled after delivery. 3, 4
• Additional colposcopic examinations during pregnancy are discouraged. 3, 4

Follow‑up After Initial Colposcopy (when CIN is not identified)

• Perform repeat cytology at 12 months. 4
• Return to routine screening after obtaining two consecutive negative cytology results. 4

Management of Low‑Grade Squamous Intraepithelial Lesion (LSIL) in Pregnancy – Evidence‑Based Recommendations

Initial Management Options

• Colposcopy during pregnancy is the preferred initial evaluation to rule out high‑grade lesions or invasive cancer, especially when reliable postpartum follow‑up is uncertain. 7
• Endocervical curettage is absolutely contraindicated in pregnant patients. 7
• Cervical biopsy should be performed only when colposcopic findings raise suspicion for CIN 2/3 or cancer. 7

Follow‑up When Initial Colposcopy Is Negative for CIN 2/3 or Cancer

• Schedule postpartum follow‑up rather than repeat colposcopic examinations during pregnancy if the initial colposcopy shows no cytologic, histologic, or colposcopic evidence of CIN 2/3 or cancer. 7
• Additional colposcopic and cytologic examinations during pregnancy are not acceptable for these women. 7
• Re‑evaluation with cytology and colposcopy should be performed no sooner than 6 weeks after delivery. 7

Biopsy Considerations

• Reserve cervical biopsy for lesions that appear suspicious for CIN 2/3 or cancer on colposcopic examination. 7

Excisional Procedures

• Diagnostic excisional procedures are unacceptable unless invasive cancer is suspected based on referral cytology, colposcopic appearance, or prior cervical biopsy. 7

Postpartum Management

• Conduct a comprehensive re‑evaluation at ≥6 weeks postpartum using both cytology and colposcopy. 7

Evidence‑Based Follow‑Up Strategies for Cervical Low‑Grade Squamous Intraepithelial Lesion (LSIL)

Adolescents (≤ 20 years)

• At the 12‑month follow‑up visit, proceed to colposcopy only if high‑grade squamous intraepithelial lesion (HSIL) or a more severe abnormality is identified on repeat cytology. 8, 9
• At the 24‑month follow‑up visit, proceed to colposcopy if atypical squamous cells of undetermined significance (ASC‑US) or any higher grade abnormality is present on cytology. 8, 9
• HPV DNA testing should not be used in this age group and must not influence management, even if performed inadvertently. 8, 9

Adult Women (21–65 years)

Repeat Cytology Strategy

• Perform cervical cytology at 6 months and 12 months after the LSIL diagnosis. 8, 9
• Refer to colposcopy if ASC‑US or any higher‑grade abnormality is detected on either repeat test. 8, 9
• Return to routine screening after two consecutive negative cytology results. 8, 9

HPV DNA Testing at 12 Months

• Conduct HPV DNA testing only at the 12‑month visit; a positive result warrants referral to colposcopy. 8, 9
• A negative HPV test at 12 months allows the patient to resume routine cervical cancer screening. 8, 9
• Because ≈ 86 % of women with LSIL are HPV‑positive, immediate HPV testing at baseline provides little discriminative value. 9

Postmenopausal Women

• If the HPV test is negative or colposcopy shows no cervical intraepithelial neoplasia (CIN), repeat cytology at 12 months. 8
• If the HPV test is positive or repeat cytology shows ASC‑US or higher, proceed to colposcopy. 8

Pregnant Women (Non‑Adolescent)

• Colposcopy is the preferred initial approach for LSIL detected during pregnancy. 8
• Endocervical curettage is absolutely contraindicated in pregnancy. 8, 9
• When the initial colposcopic examination shows no CIN 2/3 or cancer, schedule postpartum follow‑up rather than additional colposcopic examinations during pregnancy. 8

General Management Principles

• Do not perform routine excisional procedures (e.g., LEEP) for the initial management of LSIL unless histology confirms CIN 2/3. 8
• If colposcopy is unsatisfactory or negative, an endocervical assessment using a cytobrush or endocervical curette is the preferred next step. 9